PUS1 is a novel biomarker for evaluating malignancy of human renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PUS1 is a novel biomarker for evaluating malignancy of human renal cell carcinoma

Published:2023-06-13 Issue: Volume: Page:
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Li Lin¹²,Zhu Chongying³,Xu Shouying¹,Xu Qiang¹,Xu Da²,Gan Sishun²,Cui Xingang⁴,Tang Chao¹

Affiliation:

1. National Clinical Research Center for Child Health of the Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China

2. Department of Urology, Third Affiliated Hospital of the Second Military Medical University, Shanghai 201805, China

3. Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

4. Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China

Publisher

Impact Journals, LLC

Subject

Cell Biology,Aging

Reference36 articles.

1. Cancer statistics, 2019.;Jemal;CA Cancer J Clin,2019

2. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.;Horwich;Ann Oncol,2019

3. Long non-coding RNA CYTOR modulates cancer progression through miR-136-5p/MAT2B axis in renal cell carcinoma.;Yi;Toxicol Appl Pharmacol,2022

4. Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?;Kim;Clin Adv Hematol Oncol,2016

5. ZNF677 suppresses renal cell carcinoma progression through N6-methyladenosine and transcriptional repression of CDKN3.;Zhang;Clin Transl Med,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP